|
시장보고서
상품코드
1859891
세계의 관상동맥 우회술(CABG) : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Coronary Artery Bypass Grafts (CABG) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
관상동맥 우회술(CABG) 시장 규모는 2024년에 1억 4,200만 달러로 평가되었고, 2025-2031년의 예측 기간 중 CAGR 5.2%로 성장하여 2031년까지 2억 200만 달러로 확대될 것으로 예측됩니다.
관상동맥 우회술(CABG)은 일반적으로 심장우회술 또는 우회수술이라고도 하며, 막힌 관상동맥에 정상적인 혈류를 회복시키는 수술입니다.
관상동맥우회술(CABG)은 좁아지거나 막힌 관상동맥 주변에 자가 혈관 또는 대체 혈관 이식을 이용한 우회로를 형성하여 심근에 혈액 공급을 회복시키는 외과적 중재술입니다. 이를 통해 심근을 보호하고 허혈 증상을 완화하며 유해한 심장 질환의 위험을 줄일 수 있습니다. CABG는 다발성 및 복합 관상동맥 질환에 대한 표준 치료로서 전통적인 개흉술부터 정교한 최소 침습적 기술 및 보조 보조 보조 방법까지 다양하게 적용되고 있습니다. 수술 전후 생태계(이식편 보존, 수술 중 관류 관리, 지혈, 소모품, 수술 후 재활)는 의료기기, 일회용 소모품, 약리학적 보조제, 서비스 제공 등 통합 시장을 형성하고 있습니다.
심혈관 질환 부담에 대한 공중보건의 지속적인 관심은 내구성 있는 치료 결과와 장기적인 삶의 질이 중요한 CABG 분야에서 지속적인 수요 기반을 제공합니다. 이식편 보존, 수술 중 혈액 관리, 대체 이식편 재료의 혁신과 더불어 상장 기업 및 R&D 기업의 상용화가 진행됨에 따라 대상 제품 카테고리가 확대되고 있으며, 임상적 증거와 확장 가능한 제조 능력을 결합할 수 있는 기업에게 우수한 상용화 기회가 창출되고 있습니다.
주요 제약 요인으로는 엄격한 규제 요건, 장기 임상 증거의 필요성, 엄격한 품질 관리 등이 있습니다. 새로운 기기나 이식 재료는 표준 수술 경로에 채택되기 전에 일반적으로 장기간의 임상 프로그램과 규제 당국과의 대화가 필요합니다. 시판 후 안전 및 품질 문제는 컴플라이언스 비용과 브랜드 신뢰도에 심각한 영향을 미칠 수 있습니다. 공급망의 견고성, 무균 제조 능력, 병원 예산 동향도 구체적인 상업화 리스크를 가져옵니다.
이 보고서는 관상동맥우회술(CABG) 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
관상동맥우회술(CABG) 시장 규모 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 관상동맥우회술(CABG)에 대한 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 포지셔닝을 분석하고, 관상동맥우회술(CABG)에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.
시장 세분화
기업별
- Medtronic
- Getinge Group
- LivaNova
- Terumo
- Boston Scientific
- Stryker
- Edwards Lifesciences
- Genesee Biomedical
- Karl Storz GmbH
유형별 부문
- 복재정맥 그래프트
- 내흉동맥 그래프트
- 기타
용도별 부문
- 기존 CABG
- 비기존 CABG
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Coronary Artery Bypass Grafts (CABG) was estimated to be worth US$ 142 million in 2024 and is forecast to a readjusted size of US$ 202 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Coronary artery bypass surgery, also known as coronary artery bypass graft (CABG) surgery, and colloquially heart bypass or bypass surgery, is a surgical procedure to restore normal blood flow to an obstructed coronary artery.
Coronary artery bypass grafting (CABG) is a surgical intervention to restore myocardial blood supply by creating bypass conduits-using autologous or alternative vascular grafts-around narrowed or occluded coronary arteries to preserve cardiac muscle, relieve ischemic symptoms, and reduce the risk of adverse cardiac events. As a standard of care for multivessel and complex coronary disease, CABG spans from conventional open-chest on-pump procedures to refined, less invasive techniques and supporting adjuncts. The perioperative ecosystem-graft preservation, intraoperative perfusion management, hemostasis, consumables, and postoperative rehabilitation-forms an integrated market that includes devices, disposables, pharmacologic adjuncts, and service offerings.
The sustained public-health emphasis on cardiovascular disease burden provides an enduring demand base for CABG where durable outcomes and long-term quality of life matter. Innovations in graft preservation, intraoperative blood management and alternative conduit materials, together with commercialization by listed and R&D companies, are expanding addressable product categories and creating premium commercialization opportunities for firms that can pair clinical evidence with scalable manufacturing.
Major restraints include rigid regulatory requirements, the need for long-term clinical evidence, and stringent quality controls. Novel devices and graft materials typically require extended clinical programs and regulatory interactions before adoption into standard surgical pathways; post-market safety or quality issues can materially impact compliance costs and brand trust. Supply-chain robustness, sterile manufacturing capability, and hospital budget dynamics also present tangible commercialization risks.
This report aims to provide a comprehensive presentation of the global market for Coronary Artery Bypass Grafts (CABG), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Coronary Artery Bypass Grafts (CABG) by region & country, by Type, and by Application.
The Coronary Artery Bypass Grafts (CABG) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Coronary Artery Bypass Grafts (CABG).
Market Segmentation
By Company
- Medtronic
- Getinge Group
- LivaNova
- Terumo
- Boston Scientific
- Stryker
- Edwards Lifesciences
- Genesee Biomedical
- Karl Storz GmbH
Segment by Type
- Saphenous Vein Grafts
- Internal Thoracic Artery Grafts
- Other
Segment by Application
- Traditional CABG
- Nontraditional CABG
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Coronary Artery Bypass Grafts (CABG) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Coronary Artery Bypass Grafts (CABG) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Coronary Artery Bypass Grafts (CABG) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Coronary Artery Bypass Grafts (CABG) Product Introduction
- 1.2 Global Coronary Artery Bypass Grafts (CABG) Market Size Forecast (2020-2031)
- 1.3 Coronary Artery Bypass Grafts (CABG) Market Trends & Drivers
- 1.3.1 Coronary Artery Bypass Grafts (CABG) Industry Trends
- 1.3.2 Coronary Artery Bypass Grafts (CABG) Market Drivers & Opportunity
- 1.3.3 Coronary Artery Bypass Grafts (CABG) Market Challenges
- 1.3.4 Coronary Artery Bypass Grafts (CABG) Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Coronary Artery Bypass Grafts (CABG) Players Revenue Ranking (2024)
- 2.2 Global Coronary Artery Bypass Grafts (CABG) Revenue by Company (2020-2025)
- 2.3 Key Companies Coronary Artery Bypass Grafts (CABG) Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Coronary Artery Bypass Grafts (CABG) Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Coronary Artery Bypass Grafts (CABG)
- 2.6 Coronary Artery Bypass Grafts (CABG) Market Competitive Analysis
- 2.6.1 Coronary Artery Bypass Grafts (CABG) Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Coronary Artery Bypass Grafts (CABG) Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Coronary Artery Bypass Grafts (CABG) as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Saphenous Vein Grafts
- 3.1.2 Internal Thoracic Artery Grafts
- 3.1.3 Other
- 3.2 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Type
- 3.2.1 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Coronary Artery Bypass Grafts (CABG) Sales Value, by Type (2020-2031)
- 3.2.3 Global Coronary Artery Bypass Grafts (CABG) Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Traditional CABG
- 4.1.2 Nontraditional CABG
- 4.2 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Application
- 4.2.1 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Coronary Artery Bypass Grafts (CABG) Sales Value, by Application (2020-2031)
- 4.2.3 Global Coronary Artery Bypass Grafts (CABG) Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Region
- 5.1.1 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Region (2020-2025)
- 5.1.3 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Region (2026-2031)
- 5.1.4 Global Coronary Artery Bypass Grafts (CABG) Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 5.2.2 North America Coronary Artery Bypass Grafts (CABG) Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 5.3.2 Europe Coronary Artery Bypass Grafts (CABG) Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 5.4.2 Asia Pacific Coronary Artery Bypass Grafts (CABG) Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 5.5.2 South America Coronary Artery Bypass Grafts (CABG) Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Coronary Artery Bypass Grafts (CABG) Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Coronary Artery Bypass Grafts (CABG) Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.3.2 United States Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.4.2 Europe Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.5.2 China Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.6.2 Japan Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.7.2 South Korea Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.8.2 Southeast Asia Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Coronary Artery Bypass Grafts (CABG) Sales Value, 2020-2031
- 6.9.2 India Coronary Artery Bypass Grafts (CABG) Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Coronary Artery Bypass Grafts (CABG) Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Medtronic
- 7.1.1 Medtronic Profile
- 7.1.2 Medtronic Main Business
- 7.1.3 Medtronic Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.1.4 Medtronic Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.1.5 Medtronic Recent Developments
- 7.2 Getinge Group
- 7.2.1 Getinge Group Profile
- 7.2.2 Getinge Group Main Business
- 7.2.3 Getinge Group Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.2.4 Getinge Group Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.2.5 Getinge Group Recent Developments
- 7.3 LivaNova
- 7.3.1 LivaNova Profile
- 7.3.2 LivaNova Main Business
- 7.3.3 LivaNova Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.3.4 LivaNova Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.3.5 LivaNova Recent Developments
- 7.4 Terumo
- 7.4.1 Terumo Profile
- 7.4.2 Terumo Main Business
- 7.4.3 Terumo Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.4.4 Terumo Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.4.5 Terumo Recent Developments
- 7.5 Boston Scientific
- 7.5.1 Boston Scientific Profile
- 7.5.2 Boston Scientific Main Business
- 7.5.3 Boston Scientific Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.5.4 Boston Scientific Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.5.5 Boston Scientific Recent Developments
- 7.6 Stryker
- 7.6.1 Stryker Profile
- 7.6.2 Stryker Main Business
- 7.6.3 Stryker Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.6.4 Stryker Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.6.5 Stryker Recent Developments
- 7.7 Edwards Lifesciences
- 7.7.1 Edwards Lifesciences Profile
- 7.7.2 Edwards Lifesciences Main Business
- 7.7.3 Edwards Lifesciences Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.7.4 Edwards Lifesciences Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.7.5 Edwards Lifesciences Recent Developments
- 7.8 Genesee Biomedical
- 7.8.1 Genesee Biomedical Profile
- 7.8.2 Genesee Biomedical Main Business
- 7.8.3 Genesee Biomedical Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.8.4 Genesee Biomedical Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.8.5 Genesee Biomedical Recent Developments
- 7.9 Karl Storz GmbH
- 7.9.1 Karl Storz GmbH Profile
- 7.9.2 Karl Storz GmbH Main Business
- 7.9.3 Karl Storz GmbH Coronary Artery Bypass Grafts (CABG) Products, Services and Solutions
- 7.9.4 Karl Storz GmbH Coronary Artery Bypass Grafts (CABG) Revenue (US$ Million) & (2020-2025)
- 7.9.5 Karl Storz GmbH Recent Developments
8 Industry Chain Analysis
- 8.1 Coronary Artery Bypass Grafts (CABG) Industrial Chain
- 8.2 Coronary Artery Bypass Grafts (CABG) Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Coronary Artery Bypass Grafts (CABG) Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Coronary Artery Bypass Grafts (CABG) Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
